Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024: 168-174

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.168174

Advances in Bioresearch

REVIEW ARTICLE

Microbiome-based Therapies in Gastrointestinal Disorders: Promises and Challenges

[1]Sanjay Thorat, [2]Pankaj Nivrutti Pawar, [3]Dhairyasheel Patil, [4]Mahendra M. Alate, [5]Trupti Saket Bhosale

[1-3]Department of Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra

[4-5] Department of Research Krishna Vishwa Vidyapeeth, Karad,Maharashtra, India

ABSTRACT

A varied population of microorganisms known as the human gastrointestinal (GI) microbiome is essential to both health and illness. The promise and difficulties of microbiome-based therapeutics in the treatment of gastrointestinal illnesses, such as IBD, IBS, and Clostridium difficile infection (CDI), are examined in this study. A common characteristic of these conditions is dysbiosis, which is defined by disturbances in the composition and functionality of microbiota and affects the severity and course of the disease. Probiotics, prebiotics, faecal microbiota transplantation (FMT), probiotics, and microbial-based medications are examples of microbiome-based therapeutics that provide hopeful paths for intervention. FMT demonstrates its restorative potential by restoring microbial diversity and function, and is especially effective in treating recurrent CDI. By modifying the gut microbiota, probiotics and prebiotics support a healthy microbial equilibrium. Standardising procedures, guaranteeing safety, adhering to regulations, determining the best microbiological targets, and comprehending unique therapeutic responses continue to provide difficulties, nonetheless. Prospective avenues encompass tailored therapies founded on distinct gut microbiome profiles, utilising cutting-edge sequencing technology, and ethical deliberations. A thorough evaluation via clinical trials, technology developments, and regulatory frameworks is necessary for the successful implementation of microbiome-based treatments in clinical settings.

Keywords*: microbiome, gastrointestinal disorders, dysbiosis, therapies, personalized interventions.*

Received 24.10.2023 Revised 01.12.2023 Accepted 21.02.2024

How to cite this article:
Sanjay T, Pankaj N P, Dhairyasheel P, Mahendra M. A, Trupti S B. Microbiome-based Therapies in Gastrointestinal Disorders: Promises and Challenges. Adv. Biores., Vol 15 (2) March 2024: 168-174.

INTRODUCTION

Gastrointestinal Disorders and the Gut Microbiome

The human gastrointestinal tract (GI tract) is home to a vast array of bacteria known as the gut microbiome, which is a complex ecosystem. This complex assemblage of bacteria, viruses, fungi, and other microbes resides in the different GI tract niches and has a significant impact on human health and illness. Numerous studies conducted in recent years have shed light on the gut microbiome's critical function in preserving gut homeostasis and its participation in the aetiology of a wide range of gastrointestinal illnesses [1][2][3].

Function in Illness and Wellness

Physiological systems such as immunological regulation, food metabolism, and intestinal barrier integrity are all dependent on a healthy and varied gut microbiome. The complex interactions between host cells and the microbiota impact immune system development and function, allowing the body to build a tolerance to beneficial microorganisms while developing effective defences against pathogens [4].

On the other hand, dysbiosis—a term used to describe changes in the makeup and activity of the gut microbiome—has been linked to the development and course of a number of gastrointestinal illnesses [5]. Disorders like inflammatory bowel disorders (IBD), which include Crohn's disease and ulcerative colitis, show unique changes in the diversity and composition of gut microbiota [6]. Similarly, dysbiotic alterations in the gut microbiota have been linked to irritable bowel syndrome (IBS), which is characterised by bloating, changed bowel habits, and abdominal discomfort [7]. Furthermore, changes in

the gut flora after antibiotic administration frequently result in Clostridium difficile infection (CDI), a dangerous illness linked to healthcare [8].

Changes in the Micr obiome in Digestive Disorders

There has been a great deal of research done to explain the precise changes in the gut microbiota associated with these conditions. Reduced microbial diversity, changes in microbial composition at the phylum and genus levels, and modifications to functioning metabolic pathways in afflicted people have all been reported in studies using sophisticated sequencing methods [9][10]. For example, reduced microbial diversity and altered abundance of some taxa, including lower levels of Bacteroidetes and Firmicutes, have been regularly documented in IBD [1]. Similar to this, imbalances in microbial populations have also been reported in IBS [2]. These imbalances include variations in the number of particular bacterial species and the ratio of Firmicutes to Bacteroidetes.

Possibilities for Microbiome-Based Treatments

The understanding of the pivotal role the gut microbiota plays in gastrointestinal illnesses has prompted research into microbiome-based therapeutics as possible therapeutic approaches. Faecal microbiota transplantation (FMT) is one of these approaches that has attracted a lot of interest and proven to be effective, especially when used to treat recurrent CDI [3]. The goal of faecal material transfer (FMT) is to replenish a recipient's gut microbial flora by transferring it from a healthy donor. Clinical research has shown that microbial therapies can be restorative, as seen by the high rates of CDI resolution that occur after FMT [4].

Furthermore, there has been an increase in the use of probiotics and prebiotics to modify the gut microbiome in the direction of a more advantageous composition. Probiotics, which are living bacteria that benefit the host when given in sufficient quantities, and prebiotics, which are indigestible substances that specifically encourage the growth of beneficial microbes, present viable paths for therapeutic treatments [5][6]. Even while these therapies seem promising, further research is necessary to address issues with strain specificity, dosage, and long-term effects [7][8].

In an effort to harness the therapeutic potential of particular bacteria species or their metabolites in the management of gastrointestinal illnesses, ongoing research initiatives are also investigating the creation of microbial-based medications. These cutting-edge strategies aim to precisely alter the gut microbiome by focusing on important dysbiotic components linked to the aetiology of illness [9][10].

The complex interplay between gastrointestinal illnesses and the gut microbiota highlights the possibility of microbiome-based therapeutics to modify the course of disease. But even with these encouraging developments, there are still many obstacles to overcome before these treatments may be used in clinical settings. The scientific and medical community must thoroughly assess and reach an agreement about the standardisation of methods, safety concerns, legal frameworks, and ethical implications [10].

In order to effectively manage gastrointestinal problems, the field of microbiome research is changing. This is because it highlights the importance of gaining a greater understanding of the intricate workings of the gut microbiota and its potential for therapeutic intervention in order to shape the future of healthcare.

Section 1: Gastrointestinal disorders and the role of microbiome

Maintaining gastrointestinal health and contributing significantly to the pathophysiology of many gastrointestinal illnesses are two important functions of the gut microbiome, a complicated ecosystem made up of a varied array of bacteria [1][2][3].

Variations in Type and Content of Gastrointestinal Disorders

The gut microbiome exhibits remarkable variety in health, comprising an array of microbial species that collaborate to produce a stable and harmonious community. Disturbances in this delicate balance, known as dysbiosis, have been repeatedly linked to the beginning and development of gastrointestinal illnesses [4].

IBDs, or inflammatory bowel diseases:

Changes to the gut microbiota are a common aspect of inflammatory bowel illnesses (IBD), including ulcerative colitis and Crohn's disease. Research has revealed that people with IBD exhibit dysbiotic alterations in the relative abundance of particular bacterial taxa as well as decreased microbial diversity [5]. It has frequently been noted that the number of Firmicutes, especially butyrate-producing bacteria, has decreased and that the ratio of Firmicutes to Bacteroidetes has changed [6].

IBS, or irritable bowel syndrome:

In a similar vein, dysbiosis has been connected to irritable bowel syndrome (IBS), which is marked by persistent stomach discomfort, changed bowel habits, and bloating. Studies have shown changes in the microbial composition, including variations in the abundance of certain bacterial species, such as lower

levels of Faecalibacterium prausnitzii, which is renowned for its anti-inflammatory characteristics [7], even if the precise microbial fingerprints in IBS remain variable.

Infection with Clostridium difficile (CDI):

A common cause of antibiotic-associated diarrhoea and colitis is Clostridium difficile infection (CDI), which is frequently brought on by changes in the gut flora after antibiotic medication. Antibiotics alter the typical flora in the stomach, which makes C. difficult to spread and spread illness. Furthermore, those who have had antibiotic treatments frequently show decreased microbial diversity and disturbances in important bacterial species, which promotes C's colonisation and expansion. difficile [8].

Mechanisms That Underlie Microbiome Impact

Through a variety of methods, the gut microbiota influences gastrointestinal health. Its contribution to the preservation of immunological homeostasis and the integrity of the intestinal barrier is one of its primary functions. Commensal microorganisms are essential for strengthening the intestinal epithelial barrier, which stops infections and antigens from moving across it [9].

Additionally, the host immune system and the gut microbiota actively interact to affect immune cell formation, activation, and response to stimuli. In addition to building proper immune responses against possible pathogens, this reciprocal interaction between gut microorganisms and the immune system develops immunological tolerance to commensal bacteria [10].

Therapeutic Intervention Implications

The investigation of microbiome-based therapeutics as possible therapeutic approaches has been sparked by an understanding of the complex changes in the gut microbiota linked to gastrointestinal illnesses. In instances like recurrent CDI, faecal microbiota transplantation (FMT) in particular has shown promise as an intervention to restore microbial diversity and function [11]. FMT seeks to restore a balanced microbial community and hence resolve the dysbiosis linked to CDI by transferring the faecal microbiota of a healthy donor into the recipient's stomach [12].

Furthermore, there are potential therapeutic routes for the modification of the gut microbiome through the use of probiotics, which include live beneficial bacteria, and prebiotics, which act as substrates for beneficial microbes [13]. Probiotics support a healthy microbial composition by colonising the gut and interacting with the microorganisms that live there. Contrarily, prebiotics specifically support the development and activity of advantageous bacteria in the gut environment by feeding them [14].

Even while microbiome-based therapy has showed promise, understanding the complexity of the gut microbial ecology and implementing these treatments in clinical settings continue to present difficulties. The areas of inquiry that remain critical include procedure standardisation, the best choice of microbial strains, safety concerns, and long-term effectiveness evaluations [15].

Section 2: Mechanisms and Applications of Microbiome-Based Therapies

With the goal of modifying the gut microbiota for therapeutic benefit, the investigation of microbiome-based therapeutics marks a paradigm change in the treatment of gastrointestinal illnesses [1][2][3].

Transplanting Faecal Microbiota (FMT)

Faecal microbiota transplantation (FMT) is one of the most effective microbiome-based therapeutics available, especially when it comes to treating recurrent Clostridium difficile infection (CDI). Faecal material is transferred from a healthy donor to a recipient using a colonoscopy, nasogastric tube, or pill form in the case of FMT [4]. The basic idea behind FMT is to improve the dysbiosis linked to CDI by reestablishing a functioning and diversified gut microbiota [5].

FMT is an effective restorative treatment that has shown impressive success rates in treating recurrent CDI in clinical investigations [6]. Through the introduction of a healthy donor's microbial community, FMT efficiently restores microbial diversity and strengthens resistance to C colonisation. difficile, and restores a healthy gut ecology, which causes the illness to go away [7].

Contraceptives and Prebiotics

Probiotics and prebiotics are complementary to FMT and provide additional ways to modify the gut microbiome in the direction of a more advantageous composition [8]. A variety of living microorganisms, mostly bacteria like Lactobacillus and Bifidobacterium strains, are included in probiotics and can be beneficial to health when taken in sufficient amounts [9]. These probiotic strains influence microbial composition, improve barrier function, modulate immune responses, and directly interact with gut bacteria to produce their desired effects [10].

Conversely, prebiotics, which are indigestible substances such as dietary fibres and oligosaccharides, act as substrates for good bacteria in the stomach. Prebiotics support the development and activity of beneficial bacteria by feeding them specifically, which creates a more advantageous gut microbial population [11]. A healthy gut microbiota is restored and maintained in part by these synergistic interactions between probiotics and prebiotics.

Mechanisms and Uses

Microbiome-based therapies have a variety of mechanisms underpinning their therapeutic success. For example, FMT affects microbial functioning in addition to restoring microbial diversity. FMT aids in the resolution of dysbiosis-associated disorders by restoring microbial metabolic pathways and functions by the introduction of a varied pool of microbial species and their metabolic products [12].

Probiotics exhibit anti-inflammatory effects and strengthen the integrity of the intestinal barrier via modulating host-microbe and microbe-microbe interactions through colonisation and interaction with resident bacteria [13]. These activities help to reduce inflammation and enhance gut health, which may be advantageous for diseases like IBD and IBS.

Similar to this, prebiotics aid in the synthesis of short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate by specifically promoting the development and activity of advantageous microorganisms. SCFAs have positive impacts on gastrointestinal health because they support gut barrier integrity, control immunological responses, and provide energy to colonocytes [14].

Obstacles and Prospects for the Future

Although microbiome-based therapeutics have therapeutic potential, a number of obstacles prevent their broad clinical implementation. Further study and consensus are still required in the areas of procedure standardisation, donor features identification for FMT, probiotic strain and prebiotic ingredient efficacy, and dosage regimen establishment [15].

Future developments in personalised medicine, metagenomics, and microbial ecology will be used to explore more accurate and focused microbiome-based therapies. More efficient and individualised therapy may be possible by using cutting-edge sequencing technology and customising medications based on each patient's unique gut microbiome [16].

Section 3: Difficulties with Therapies Based on the Microbiome

Although microbiome-based treatments have potential for treating gastrointestinal illnesses, a number of obstacles prevent them from being successfully implemented in clinical settings [1][2][3].

Protocol Standardisation

Standardising procedures for microbiome-based therapies is one of the biggest problems. The establishment of consistent and optimal protocols is hampered by variations in FMT processes, such as donor selection criteria, preparation techniques, and administration routes [4]. In order to maximise the possible hazards involved with these medicines while ensuring repeatability and efficacy, it is imperative to reach consensus on standardised protocols across clinical settings.

Safety Points to Remember

One major problem with microbiome-based medicines is their safety profile. Even though FMT has shown great success in treating recurrent CDI, few side effects have been documented. Thorough safety evaluations are crucial because of reports of brief gastrointestinal problems, infections, and possible infection or antibiotic resistance gene transfer from donors to recipients [5]. It is critical for the clinical use of these medicines to ensure their safety through thorough donor screening, product quality control, and adverse event monitoring.

Ethics and Regulation Concerns

Overcoming ethical dilemmas and regulatory frameworks is a major obstacle to the use of microbiome-based treatments. The regulatory processes for FMT's approval and commercialization are influenced by whether regulatory bodies classify it as a drug or a biological product [6]. To enable the integration of these medicines into clinical practice while maintaining ethical standards and patient safety, it is imperative to establish explicit regulatory rules and ethical frameworks that strike a balance between the safety, accessibility, and cost of these therapies.

Selecting the Best Microbial Targets

It's still difficult to identify the best microbiological targets for therapy. It is imperative to have a greater knowledge of the precise microbial signatures linked to disease states and treatment responses due to the tremendous complexity and inter-individual diversity of the gut microbiome [7]. For these treatments to be effective and safe, it is essential to identify and target important microbial species or functional pathways involved in the pathogenesis of illness while maintaining beneficial microbial ecosystems.

Customised Reactions to Treatments

One major problem with microbiome-based medicines is the heterogeneity in individual reactions. Inter-individual differences in treatment results are caused by a number of factors, including food, host genetics, baseline microbial composition, and environmental impacts [8]. One of the most important areas for research and clinical application is the development of techniques for personalised therapies that take

into account unique host characteristics and gut bacteria profiles to predict treatment responses and maximise therapeutic efficacy.

Effects Over Time and Intentional Repercussions

It is critical to evaluate the possible side effects and long-term implications of microbiome-based therapeutics. Concerns concerning the durability of therapeutic benefits, ecological stability of imported microbial communities, and unanticipated adverse effects on host health are raised by the dynamic nature of the gut microbiome and its interactions with host physiology [9]. To clarify the long-term effectiveness and safety profiles of these medicines, longitudinal studies assessing their sturdiness, safety, and wider effects are crucial.

Section 4: Future Prospects and Clinical Effectiveness

Clinical Evaluation of Therapies Based on the Microbiome

An essential component of integrating microbiome-based medicines into routine clinical practice is evaluating their clinical efficacy in treating gastrointestinal illnesses [1][2][3].

Extensive Clinical Trials

It is essential to conduct thorough clinical studies assessing the long-term effects, safety, and effectiveness of microbiome-based treatments. It is crucial to conduct extensive randomised controlled trials (RCTs) to determine the efficacy of treatments like FMT, probiotics, prebiotics, and microbial-based medications across a range of patient groups [4]. Standardised procedures, thorough outcome measurements, and long follow-up times should all be used in these studies to determine the therapeutic benefits that are both short- and long-lasting.

Clinical Effectiveness in Particular Illnesses

It is important to evaluate the relative effectiveness of microbiome-based treatments for particular gastrointestinal conditions. Irritable bowel syndrome (IBS), Clostridium difficile infection (CDI), and other disorders that are the subject of clinical studies ought to clarify the subtleties of treatment responses, the patient subgroups that benefit most, and the variables affecting therapy results [5].

Extended Observation and Security

Patients receiving microbiome-based therapeutics must be closely watched over an extended period of time in order to evaluate the long-term sustainability of the therapeutic benefits and identify any possible side effects or consequences [6]. Comprehensive evaluations of the gut microbial composition, rates of illness recurrence, and the overall effect on the health and well-being of patients should all be included in post-treatment surveillance.

Prospective Pathways and Progress

Tailored Microbiome-Based Treatments

Therapeutics based on the individual microbiota are made possible by developments in bioinformatics and omics technology. Individual gut microbial profiles may be characterised by using high-throughput sequencing and computational methods. This makes it possible to design customised therapies that take into account each patient's particular microbiome composition, host variables, and disease features [7].

Microbiome as a Target for Therapy

Increasing our knowledge of the complex relationships that exist between host physiology and the gut microbiota offers potential avenues for new therapeutic targets. Developing precise and focused therapies may be possible by focusing on certain dysbiotic components or microbial pathways linked to the pathophysiology of illness [8].

Including Cutting-Edge Technologies

A greater knowledge of the functional capacities and metabolic activities of gut bacteria is made possible by the use of cutting-edge technologies, such as metagenomics, metatranscriptomics, and metabolomics, into clinical research. With the use of these technologies, illness pathophysiology and treatment responses can be better understood, leading to the creation of more potent treatments [9].

Regulatory and Ethical Frameworks

The establishment of strong ethical and regulatory frameworks is still essential to the ethical and fair use of microbiome-based therapeutics. In order to guarantee patient safety, accessibility, cost, and ethical concerns in the development and implementation of new medicines, collaborative efforts including researchers, physicians, regulatory authorities, and ethicists are required [10].

Section 5: Final Thoughts

The complex relationship between gastrointestinal illnesses and the gut microbiota highlights the enormous promise of microbiome-based therapeutics as game-changing approaches to disease management [1][2][3].

The importance of gut microbiota

The gastrointestinal tract's gut microbiome, a dynamic and multifaceted ecology of bacteria, has a significant impact on immunological responses, host physiology, and disease susceptibility [4]. Inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and Clostridium difficile infection (CDI) are among the gastrointestinal ailments that have been repeatedly linked to dysbiosis, which is defined by abnormalities in microbial composition and functioning [5].

The Potential of Microbiome-Based Treatments

Probiotics, prebiotics, faecal microbiota transplantation (FMT), and microbial-based medications are examples of microbiome-based therapeutics that provide viable means of modifying the gut microbiome in order to restore equilibrium and lessen the burden of illness [6].

Restoring microbial diversity and function with FMT has demonstrated impressive success rates in controlling recurrent CDI, underlining the therapeutic potential of gut microbiota restoration [7].

Similarly, probiotics and prebiotics are effective treatments for fostering a healthy gut microbiota and reducing symptoms related to gastrointestinal illnesses by altering microbial populations and metabolic processes [8].

Obstacles and Things to Think About

However, there are several obstacles to overcome before microbiome-based treatments may be used in clinical settings. Critical aspects that require thorough exploration and resolution include standardising processes, guaranteeing safety, navigating regulatory frameworks, finding ideal microbiological targets, comprehending customised responses, and evaluating long-term impacts [9].

Prospective Courses

Personalised microbiome-based treatments that are adapted to each patient's unique gut microbiota profiles have the potential to improve treatment outcomes and reduce side effects in the future [10]. Cutting-edge technology, such as computational tools and omics methods, will help uncover new treatment targets and advance our knowledge of the functional functions of the gut microbiota.

Furthermore, it is crucial to build ethical and legal frameworks that guarantee patient safety, fair access, and ethical concerns throughout the creation and use of new treatments [11].

Potential for Transformation

Finally, the critical involvement of the gut microbiota in gastrointestinal illnesses provides a framework for novel treatment approaches. By addressing the underlying causes of gastrointestinal illnesses and moving the emphasis towards comprehensive and individualised methods, microbiome-based therapeutics represent a rapidly emerging field with revolutionary potential that has the ability to completely change the way sickness is managed.

However, to fully realise the promise of microbiome-based therapies, interdisciplinary stakeholders must work together to overcome obstacles and navigate the uncertainties that come with this developing field. This will require rigorous scientific inquiry, technological advancements, and ethical considerations [12].

REFERENCES

1. Sender, R., Fuchs, S., & Milo, R. (2016). Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. *Cell, 164*(3), 337–340. DOI: 10.1016/j.cell.2016.01.013
2. Lynch, S. V., & Pedersen, O. (2016). The Human Intestinal Microbiome in Health and Disease. *New England Journal of Medicine, 375*(24), 2369–2379. DOI: 10.1056/NEJMra1600266
3. Marchesi, J. R., & Ravel, J. (2015). The vocabulary of microbiome research: a proposal. *Microbiome, 3*, 31. DOI: 10.1186/s40168-015-0094-5
4. Peterson, J., Garges, S., Giovanni, M., et al. (2009). The NIH Human Microbiome Project. *Genome Research, 19*(12), 2317–2323. DOI: 10.1101/gr.096651.109
5. Qin, J., Li, R., Raes, J., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature, 464*(7285), 59–65. DOI: 10.1038/nature08821
6. Kelly, C. R., Kahn, S., Kashyap, P., et al. (2015). Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. *Gastroenterology, 149*(1), 223–237. DOI: 10.1053/j.gastro. 2015.05.008
7. Hill, C., Guarner, F., Reid, G., et al. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology & Hepatology, 11*(8), 506–514. DOI: 10.1038/nrgastro.2014.66
8. Gibson, G. R., Hutkins, R., Sanders, M. E., et al. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nature Reviews Gastroenterology & Hepatology, 14*(8), 491–502. DOI: 10.1038/nrgastro.2017.75
9. Smits, L. P., Bouter, K. E., de Vos, W. M., et al. (2013). Therapeutic potential of fecal microbiota transplantation. *Gastroenterology, 145*(5), 946–953. DOI: 10.1053/j.gastro.2013.08.058
10. Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience, 13*(10), 701–712. DOI: 10.1038/nrn3346

11. Vindigni, S. M., & Surawicz, C. M. (2017). Fecal Microbiota Transplantation. Gastroenterology Clinics of North America, 46(1), 171–185. DOI: 10.1016/j.gtc.2016.09.012
12. Halmos, E. P., & Gibson, P. R. (2019). Dietary Management of Irritable Bowel Syndrome: A Review of Randomized Controlled Trials. Journal of Gastroenterology and Hepatology, 34(5), 767–777. DOI: 10.1111/jgh.14525
13. Gareau, M. G., Sherman, P. M., & Walker, W. A. (2010). Probiotics and the Gut Microbiota in Intestinal Health and Disease. Nature Reviews Gastroenterology & Hepatology, 7(9), 503–514. DOI: 10.1038/nrgastro.2010.117
14. Cao, Y., & Shen, J. (2019). Effect of Probiotic Supplementation on Relapse in Patients with Inflammatory Bowel Disease: A Meta-analysis. Canadian Journal of Gastroenterology and Hepatology, 2019, 1–10. DOI: 10.1155/2019/5735379
15. Seekatz, A. M., & Young, V. B. (2014). Clostridium difficile and the Microbiota. Journal of Clinical Investigation, 124(10), 4182–4189. DOI: 10.1172/JCI72336
16. Zmora, N., Suez, J., & Elinav, E. (2019). You Are What You Eat: Diet, Health and the Gut Microbiota. Nature Reviews Gastroenterology & Hepatology, 16(1), 35–56. DOI: 10.1038/s41575-018-0061-2